Search Results - "Strating, Esther"
-
1
Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer
Published in Frontiers in immunology (16-05-2023)“…Poor prognosis in colon cancer is associated with a high content of cancer-associated fibroblasts (CAFs) and an immunosuppressive tumor microenvironment. The…”
Get full text
Journal Article -
2
Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging
Published in British journal of cancer (01-07-2022)“…Background In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of…”
Get full text
Journal Article -
3
Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
Published in PET clinics (01-07-2023)“…Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast…”
Get full text
Journal Article -
4
Detection of Experimental Colorectal Peritoneal Metastases by a Novel PDGFRβ-Targeting Nanobody
Published in Cancers (01-09-2022)“…Peritoneal metastases in colorectal cancer (CRC) belong to Consensus Molecular Subtype 4 (CMS4) and are associated with poor prognosis. Conventional imaging…”
Get full text
Journal Article -
5
Onward Spread from Liver Metastases Is a Major Cause of Multi-Organ Metastasis in a Mouse Model of Metastatic Colon Cancer
Published in Cancers (06-03-2024)“…Colorectal cancer metastasizes predominantly to the liver but also to the lungs and the peritoneum. The presence of extra-hepatic metastases limits curative…”
Get full text
Journal Article -
6
Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68 Ga-FAPI-PET imaging
Published in British journal of cancer (16-03-2022)“…In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of CMS4 is…”
Get full text
Journal Article